Acumen Pharmaceuticals (NASDAQ:ABOS) Research Coverage Started at BTIG Research

BTIG Research assumed coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOSGet Score) in a research report sent to traders on Friday, The Fly reviews. The brokerage issued a buy ranking and a $15.00 price tag concentrate on on the inventory.

Other analysts have also issued investigate studies about the stock. Credit Suisse Team lowered their rate goal on shares of Acumen Prescribed drugs from $26.00 to $17.00 and set an outperform rating for the organization in a report on Tuesday, March 29th. HC Wainwright initiated protection on Acumen Pharmaceuticals in a report on Thursday, June 30th. They set a acquire rating and a $15.00 rate aim for the organization. 6 analysts have rated the stock with a buy rating, Based mostly on facts from MarketBeat, Acumen Prescribed drugs has an normal score of Obtain and a consensus target price of $19.17.

Acumen Prescribed drugs Buying and selling Up .5 %

Shares of ABOS opened at $6.29 on Friday. The business’s 50-day going common is $4.06 and its 200-working day moving regular is $4.70. Acumen Prescription drugs has a fifty-two week low of $3.02 and a fifty-two week high of $20.29.

Acumen Prescription drugs (NASDAQ:ABOSGet Ranking) last posted its quarterly earnings info on Monday, Could 16th. The business documented ($.23) earnings for each share (EPS) for the quarter. Provide-side analysts predict that Acumen Prescription drugs will post -.97 EPS for the present fiscal yr.

Institutional Buyers Weigh In On Acumen Prescribed drugs

A number of institutional buyers have not too long ago added to or decreased their stakes in the company. Fiduciary Group LLC ordered a new stake in Acumen Prescribed drugs in the initially quarter value $31,000. New York Point out Widespread Retirement Fund purchased a new stake in shares of Acumen Pharmaceuticals in the fourth quarter valued at $37,000. California Condition Teachers Retirement System lifted its holdings in shares of Acumen Pharmaceuticals by 114.9% in the 1st quarter. California Condition Lecturers Retirement Process now owns 12,162 shares of the company’s inventory worthy of $48,000 following purchasing an further 6,503 shares all through the time period. American Global Team Inc. grew its stake in Acumen Prescription drugs by 163.3% during the 1st quarter. American International Team Inc. now owns 14,047 shares of the company’s stock value $55,000 following acquiring an additional 8,712 shares throughout the past quarter. At last, Prelude Money Administration LLC acquired a new stake in Acumen Prescribed drugs for the duration of the 1st quarter worthy of about $61,000. 64.42% of the stock is owned by institutional traders.

Acumen Pharmaceuticals Organization Profile

(Get Score)

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the remedy of Alzheimer’s illness. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Stage I clinical-stage to focus on soluble amyloid-beta oligomers.

Even more Looking through

The Fly logo

Analyst Recommendations for Acumen Pharmaceuticals (NASDAQ:ABOS)

Receive News & Rankings for Acumen Prescribed drugs Everyday – Enter your e-mail handle below to obtain a concise every day summary of the most up-to-date information and analysts’ scores for Acumen Prescription drugs and connected companies with’s Totally free every day e mail newsletter.